Hematological abnormalities in clinically diagnosed non-alcoholic steatohepatitis: prevalence, clinical correlates, and fibrosis risk in a case–control study from Qatar - Takeaways - MDSpire

Hematological abnormalities in clinically diagnosed non-alcoholic steatohepatitis: prevalence, clinical correlates, and fibrosis risk in a case–control study from Qatar

  • By

  • Aisha Al-Khinji

  • Dhafer Malouche

  • Noof Al-Thani

  • Azza Mustafa

  • Jazeel Abdulmajeed

  • Mohamed Ghaith Al-Kuwari

  • May 8, 2026

  • 0 min

Share

  • 1

    Hematological abnormalities are prevalent in patients with clinically diagnosed non-alcoholic steatohepatitis (NASH), occurring more frequently than in matched controls.

  • 2

    Thrombocytopenia is significantly more common in NASH patients, with a prevalence of 15.4% compared to 2.5% in controls, indicating a strong association.

  • 3

    Anemia, neutropenia, and abnormal platelet counts are more prevalent in older NASH patients, women, and those with diabetes.

  • 4

    Higher FIB-4 fibrosis scores correlate with increased odds of anemia and abnormal platelets, suggesting a link to advanced fibrosis.

  • 5

    Routine complete blood count assessments may help identify NASH patients at higher risk for significant liver disease in primary care settings.

Original Source(s)

Hematological abnormalities in clinically diagnosed non-alcoholic steatohepatitis: prevalence, clinical correlates, and fibrosis risk in a case–control study from Qatar

  • by Aisha Al-Khinji, Dhafer Malouche, Noof Al-Thani, Azza Mustafa, Jazeel Abdulmajeed, Mohamed Ghaith Al-Kuwari

  • May 8, 2026

Related Content

Schisandra chinensis Fructus and its active metabolites for the treatment of metabolic dysfunction-associated steatotic liver disease

Optimizing healthcare resources in pyogenic liver abscess: a dual-threshold HDL-CRP model for predicting hospitalization duration across multi-cohorts

Case Report: Atypical hepatobiliary manifestations associated with erythrocyte membrane instability in glucose transporter type 1 deficiency syndrome